WallStreetZenWallStreetZen

NYSEMKT: INFU
Infusystem Holdings Inc Stock

$8.80+0.29 (+3.41%)
Updated Mar 27, 2024
INFU Price
$8.80
Fair Value Price
N/A
Market Cap
$186.42M
52 Week Low
$7.45
52 Week High
$11.44
P/E
293.33x
P/B
3.62x
P/S
1.66x
PEG
37.72x
Dividend Yield
N/A
Revenue
$122.84M
Earnings
$907.00k
Gross Margin
52.4%
Operating Margin
3.07%
Profit Margin
0.7%
Debt to Equity
0.98
Operating Cash Flow
$11M
Beta
0.87
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A

INFU Overview

InfuSystem Holdings, Inc. engages in the provision of health care services. The company is headquartered in Madison Heights, Michigan and currently employs 238 full-time employees. The firm delivers local, field-based customer support and also operates pump service and repair Centers of Excellence in Michigan, Kansas, California, Texas and Ontario, Canada. Its service is to supply electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics and hospital outpatient chemotherapy clinics for the treatment of a range of cancers, including colorectal cancer, pain management and other disease states. The company sells or rents new and pre-owned pole mounted and ambulatory infusion pumps to, and provides biomedical recertification, maintenance and repair services for oncology practices, as well as other alternate site settings, including home care and home infusion providers, skilled nursing facilities, pain centers and others.

Zen Score

–
Industry Average (31)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how INFU scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

INFU ($8.80) is trading above its intrinsic value of $0.25, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
INFU is poor value based on its earnings relative to its share price (293.33x), compared to the US market average (44.45x)
P/E vs Market Valuation
INFU is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more INFU due diligence checks available for Premium users.

Be the first to know about important INFU news, forecast changes, insider trades & much more!

Valuation

INFU price to earnings (PE)

For valuing profitable companies with steady earnings
Company
293.33x
Industry
53.29x
Market
44.45x
INFU is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
INFU is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation

INFU price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
3.62x
Industry
3.74x
INFU is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

INFU price to earnings growth (PEG)

For valuing profitable companies with growth potential
INFU is poor value relative... subscribe to Premium to read more.
PEG Value Valuation

INFU's financial health

Profit margin

Revenue
$31.9M
Net Income
$689.0k
Profit Margin
2.2%
INFU's Earnings (EBIT) of $3.77M... subscribe to Premium to read more.
Interest Coverage Financials
INFU's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$102.1M
Liabilities
$50.6M
Debt to equity
0.98
INFU's short-term assets ($29.72M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INFU's long-term liabilities ($36.33M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INFU's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
INFU's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$4.3M
Investing
-$300.0k
Financing
-$3.9M
INFU's operating cash flow ($11.13M)... subscribe to Premium to read more.
Debt Coverage Financials

INFU vs Medical Stocks

TickerMarket Cap1d %P/EP/B
INFU$186.42M+3.41%293.33x3.62x
HBIO$182.28M+4.48%-52.50x2.49x
STXS$206.14M+0.80%-9.30x12.61x
ANGO$227.17M+5.56%-16.29x0.57x
AKYA$232.44M+2.16%-3.31x4.32x

Infusystem Holdings Stock FAQ

What is Infusystem Holdings's quote symbol?

(NYSEMKT: INFU) Infusystem Holdings trades on the NYSEMKT under the ticker symbol INFU. Infusystem Holdings stock quotes can also be displayed as NYSEMKT: INFU.

If you're new to stock investing, here's how to buy Infusystem Holdings stock.

What is the 52 week high and low for Infusystem Holdings (NYSEMKT: INFU)?

(NYSEMKT: INFU) Infusystem Holdings's 52-week high was $11.44, and its 52-week low was $7.45. It is currently -23.1% from its 52-week high and 18.12% from its 52-week low.

How much is Infusystem Holdings stock worth today?

(NYSEMKT: INFU) Infusystem Holdings currently has 21,183,526 outstanding shares. With Infusystem Holdings stock trading at $8.80 per share, the total value of Infusystem Holdings stock (market capitalization) is $186.42M.

Infusystem Holdings stock was originally listed at a price of $3.75 in Dec 27, 2007. If you had invested in Infusystem Holdings stock at $3.75, your return over the last 16 years would have been 134.67%, for an annualized return of 5.48% (not including any dividends or dividend reinvestments).

How much is Infusystem Holdings's stock price per share?

(NYSEMKT: INFU) Infusystem Holdings stock price per share is $8.80 today (as of Mar 27, 2024).

What is Infusystem Holdings's Market Cap?

(NYSEMKT: INFU) Infusystem Holdings's market cap is $186.42M, as of Mar 28, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Infusystem Holdings's market cap is calculated by multiplying INFU's current stock price of $8.80 by INFU's total outstanding shares of 21,183,526.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.